Compare Stocks: DIGP, ADXN, INM, and SBFM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$3.65 -1.6%	$5.37	$3.40 ▼ $12.05	$4.57M	1.47	409,714 shs	133,982 shs
DIGP Hypha Labs	$0.00 -13.5%	$0.01	$0.01 ▼ $0.07	$1.19M	0.43	99,466 shs	300,286 shs
INM InMed Pharmaceuticals	$1.38 +3.8%	$1.52	$0.58 ▼ $2.50	$4.41M	0.98	82,781 shs	7,486 shs
SBFM Sunshine Biopharma	$1.14 +2.7%	$1.51	$1.01 ▼ $24.30	$4.30M	1.17	1.25 million shs	81,274 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	+5.40%	-3.64%	-34.80%	-42.93%	-53.60%
DIGP Hypha Labs	-11.86%	-35.80%	-72.19%	-55.25%	-81.43%
INM InMed Pharmaceuticals	-1.48%	-6.99%	-10.74%	-15.82%	-36.97%
SBFM Sunshine Biopharma	-5.13%	-12.60%	-15.27%	-54.88%	-92.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$3.65 -1.6%	$5.37	$3.40 ▼ $12.05	$4.57M	1.47	409,714 shs	133,982 shs
DIGP Hypha Labs	$0.00 -13.5%	$0.01	$0.01 ▼ $0.07	$1.19M	0.43	99,466 shs	300,286 shs
INM InMed Pharmaceuticals	$1.38 +3.8%	$1.52	$0.58 ▼ $2.50	$4.41M	0.98	82,781 shs	7,486 shs
SBFM Sunshine Biopharma	$1.14 +2.7%	$1.51	$1.01 ▼ $24.30	$4.30M	1.17	1.25 million shs	81,274 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	+5.40%	-3.64%	-34.80%	-42.93%	-53.60%
DIGP Hypha Labs	-11.86%	-35.80%	-72.19%	-55.25%	-81.43%
INM InMed Pharmaceuticals	-1.48%	-6.99%	-10.74%	-15.82%	-36.97%
SBFM Sunshine Biopharma	-5.13%	-12.60%	-15.27%	-54.88%	-92.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	1.00	Sell	N/A	N/A
DIGP Hypha Labs	0.00	N/A	N/A	N/A
INM InMed Pharmaceuticals	1.00	Sell	N/A	N/A
SBFM Sunshine Biopharma	2.00	Hold	$70.00	6,040.35% Upside

Current Analyst Ratings Breakdown

Latest DIGP, ADXN, INM, and SBFM Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/25/2026	SBFM Sunshine Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/11/2026	SBFM Sunshine Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/17/2026	SBFM Sunshine Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	ADXN Addex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	INM InMed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$210K	21.38	N/A	N/A	$4.67 per share	0.78
DIGP Hypha Labs	$2.70M	0.19	N/A	N/A	($0.03) per share	-0.15
INM InMed Pharmaceuticals	$4.94M	0.92	N/A	N/A	$6.71 per share	0.21
SBFM Sunshine Biopharma	$36.31M	0.12	N/A	N/A	$7.10 per share	0.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	-$8.12M	-$5.94	N/A	N/A	N/A	N/A	-134.76%	-106.00%	11/9/2026 (Estimated)
DIGP Hypha Labs	$250K	N/A	N/A	N/A	N/A	N/A	N/A	-35.56%	N/A
INM InMed Pharmaceuticals	-$8.16M	-$2.89	N/A	N/A	N/A	-132.87%	-80.85%	-68.11%	9/23/2026 (Estimated)
SBFM Sunshine Biopharma	-$5.97M	-$10.15	N/A	N/A	N/A	-17.94%	-26.36%	-20.60%	11/12/2026 (Estimated)

Latest DIGP, ADXN, INM, and SBFM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
9/23/2026	Q4 2026	INM InMed Pharmaceuticals	-$94.4436	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	SBFM Sunshine Biopharma	-$1.20	-$1.15	+$0.05	-$1.15	$8.70 million	$9.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
DIGP Hypha Labs	N/A	N/A	N/A	N/A	N/A
INM InMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SBFM Sunshine Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	0.97	0.97
DIGP Hypha Labs	N/A	0.91	0.91
INM InMed Pharmaceuticals	N/A	3.12	3.12
SBFM Sunshine Biopharma	N/A	5.46	3.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
DIGP Hypha Labs	N/A
INM InMed Pharmaceuticals	20.12%
SBFM Sunshine Biopharma	41.98%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
DIGP Hypha Labs	10.80%
INM InMed Pharmaceuticals	0.85%
SBFM Sunshine Biopharma	0.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.23 million	1.05 million	Not Optionable
DIGP Hypha Labs	20	114.71 million	102.32 million	Not Optionable
INM InMed Pharmaceuticals	10	3.31 million	3.29 million	Not Optionable
SBFM Sunshine Biopharma	3	3.88 million	3.86 million	Not Optionable

DIGP, ADXN, INM, and SBFM Headlines

Recent News About These Companies

Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions

August 31, 2026 | accessnewswire.comA

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026 | markets.businessinsider.com

Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer

August 26, 2026 | accessnewswire.comA

Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market

August 19, 2026 | accessnewswire.comA

Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market

August 7, 2026 | accessnewswire.comA

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval

August 4, 2026 | accessnewswire.comA

EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval

August 4, 2026 | benzinga.com

Sunshine Biopharma Inc.: Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting

July 30, 2026 | finanznachrichten.de

Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting

July 28, 2026 | accessnewswire.comA

Sunshine Biopharma Inc.: Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

July 20, 2026 | finanznachrichten.de

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

July 20, 2026 | accessnewswire.comA

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)

June 25, 2026 | accessnewswire.comA

Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)

June 1, 2026 | accessnewswire.comA

Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology

May 29, 2026 | accessnewswire.comA

Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing

May 28, 2026 | accessnewswire.comA

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin

May 21, 2026 | accessnewswire.comA

Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering

May 19, 2026 | accessnewswire.comA

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

May 18, 2026 | accessnewswire.comA

SBFM Share News Today

May 15, 2026 | uk.investing.com

Sunshine Biopharma Delays Annual SEC Filing

April 14, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DIGP, ADXN, INM, and SBFM Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$3.65 -0.06 (-1.62%)

As of 04:00 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Hypha Labs OTCMKTS:DIGP

$0.0045 0.00 (-13.46%)

As of 09/3/2026

Hypha Labs, Inc., cultivates, produces, and sells psychedelic and functional mushroom in the United States. It has developed technology that quickly cultivates the mycelium root structures of psilocybin mushrooms and other functional mushroom's mycelium into a natural product. The company was incorporated in 2010 and is headquartered in Las Vegas, Nevada.

InMed Pharmaceuticals NASDAQ:INM

$1.38 +0.05 (+3.76%)

As of 04:00 PM Eastern

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Sunshine Biopharma NASDAQ:SBFM

$1.14 +0.03 (+2.70%)

As of 04:00 PM Eastern

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DIGP, ADXN, INM, and SBFM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DIGP, ADXN, INM, and SBFM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DIGP, ADXN, INM, and SBFM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DIGP, ADXN, INM, and SBFM Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Hypha Labs OTCMKTS:DIGP

InMed Pharmaceuticals NASDAQ:INM

Sunshine Biopharma NASDAQ:SBFM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DIGP, ADXN, INM, and SBFM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DIGP, ADXN, INM, and SBFM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DIGP, ADXN, INM, and SBFM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DIGP, ADXN, INM, and SBFM Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Hypha Labs OTCMKTS:DIGP

InMed Pharmaceuticals NASDAQ:INM

Sunshine Biopharma NASDAQ:SBFM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools